Organ-specific responses to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

• Published in: Journal of clinical oncology Vol. 40; no. 16_suppl; p. 4076
• Main Authors: Cheon, Jaekyung, Jung, Sanghoon, Kang, Beodeul, Kim, Hyeyeong, Kim, Chan, Chon, Hongjae
• Format: Journal Article
• Language: English
• Published: 01.06.2022

4076 Background: Anti-PD-1 monotherapy elicits various organ-specific immune responses. Although advanced hepatocellular carcinoma (aHCC) showed 20–40% objective response rates (ORR) for cases of extrahepatic lesions in sites such as the lungs or lymph nodes (LNs), only 10% of intrahepatic lesions r...